Finance

Lists
PTCT:NASDAQ
PTC Therapeutics, Inc.
$73.31
+3.47%
(+2.46) 1D
$72.00
-1.79% (-1.31)
After hours
Closed: Aug 7, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PTCT...
Open
$71.71
High
$73.37
Low
$70.95
Mkt. cap
6.12B
Avg. vol.
1.84M
Volume
963.18K
52-wk high
$90.86
52-wk low
$43.18
EPS
-$0.47
Beta
0.56
Shares outstanding
83.46M
No. of employees
991
Open
$71.71
High
$73.37
Low
$70.95
Mkt. cap
6.12B
Avg. vol.
1.84M
Volume
963.18K
52-wk high
$90.86
52-wk low
$43.18
EPS
-$0.47
Beta
0.56
Shares outstanding
83.46M
No. of employees
991
News stories
From sources across the web
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com
Analyst ratings
Based on 11 analysts giving stock ratings to PTCT in the past 3 months
Buy
Buy
9
Hold
1
Sell
1
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for PTCT in the last 3 months.
Highest
Current $73.31
$130.00 (+77.33%)
Average
$98.64 (+34.55%)
Lowest
$70.00 (-4.52%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eliana Merle
Barclays
Buy
Maintained
$120.00
+63.7%
08/03/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$130.00
+77.3%
07/30/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$85.00
+15.9%
07/30/2026
Paul Choi
Goldman Sachs
Sell
Maintained
$70.00
-4.5%
07/30/2026
Judah Frommer
Morgan Stanley
Buy
Maintained
$104.00
+41.9%
07/31/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$96.00
+31%
07/30/2026
Benjamin Burnett
Wells Fargo
Buy
Reiterated
$106.00
+44.6%
07/31/2026
Joseph Thome
TD Cowen
Buy
Maintained
$90.00
+22.8%
07/30/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$91.00
+24.1%
07/13/2026
Eric Joseph
Citi
Buy
Initiated
$108.00
+47.3%
06/10/2026
Faisal Khurshid
Jefferies
Buy
Upgraded
$85.00
+15.9%
05/27/2026
Tiago Fauth
Raymond James
Buy
Maintained
$95.00
+29.6%
05/08/2026
Geoff Meacham
Citi
Hold
Maintained
$75.00
+2.3%
05/07/2026
Unknown Analyst
Raymond James
Buy
Initiated
$108.00
+47.3%
04/09/2026
Joon Lee
Truist Financial
Buy
Maintained
-
-
02/27/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
02/20/2026
Last report
Jul 30, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.92 / $0.34
+170.59%beat
Revenue / Est. (USD)
360.52M / 298.63M
+20.72%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
211.01M
164.68M
272.55M
360.52M
Cost of goods sold
115.94M
140.08M
129.70M
119.07M
Cost of revenue
115.94M
140.08M
129.70M
119.07M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
84.05M
96.87M
86.18M
80.63M
Operating expense
91.58M
106.22M
97.76M
92.47M
Total operating expenses
207.52M
246.30M
227.46M
211.54M
Operating income
3.49M
-81.62M
45.09M
148.98M
Other non operating income
102.00K
-7.65M
-1.00M
35.00K
EBT including unusual items
-23.07M
-139.08M
-2.46M
97.54M
EBT excluding unusual items
-31.40M
-150.16M
-3.55M
100.93M
Income tax expense
-38.97M
-4.12M
347.00K
14.05M
Effective tax rate
168.89%
2.96%
-14.09%
14.40%
Other operating expenses
-
-
-
-
Net income
15.90M
-134.96M
-2.81M
83.50M
Net profit margin
7.53%
-81.96%
-1.03%
23.16%
Earnings per share
0.19
-1.80
-0.03
0.92
Interest and investment income
19.09M
2.14M
17.98M
18.12M
Interest expense
-51.68M
-57.32M
-67.02M
-66.60M
Net interest expenses
-32.59M
-55.19M
-49.03M
-48.48M
Depreciation and amortization charges
-
-
-
-
EBITDA
14.60M
-68.72M
60.50M
164.85M
Gain or loss from assets sale
53.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps